The BBI Group, partner to the world’s leading diagnostic and healthcare organisations, has entered into a definitive agreement to acquire the Maine Biotechnology Services, Inc. (MBS) located in Portland, Maine (USA).

The acquisition of MBS will expand BBI’s portfolio during a period of expansion and growth. The company provides a range of products to the diagnostic, healthcare, research food sectors globally. MBS will add antibody development to its capability and product range.

Lyn Rees, CEO of the BBI Group, said: “The acquisition of MBS perfectly complements our current product portfolio and coincides with our commercial team expansion, giving us important new technology and products.

“We are very excited about future growth potential for the business.  We expect to develop new products for our customers and directly for BBI and I am hugely excited by the opportunity to increase the services we provide for our customers. This will in turn underpin our business for many years to come.”

Dr. Joseph Chandler, Founder and President of MBS, said: “The BBI Group was aware of our reputation in the market for high quality antibody products services. They currently have no capacity for antibody development and manufacture and, with a waiting customer base for this, MBS is a logical addition to their business. They are on an ambitious growth plan and I know that MBS will be a key part of their future plans.”